Palo Alto – June 24, 2021 – Cooley advised Shoreline Biosciences, a biotechnology company developing immunotherapies for cancer and other serious diseases, on its worldwide strategic collaboration with BeiGene to develop and commercialize a portfolio of natural killer-based cell therapeutics. Lawyers Charity Williams and Bin Wang led the Cooley team advising Shoreline.
Under the terms of the agreement, Shoreline will receive an upfront payment of $45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based upon the achievement of certain development, regulatory and commercial milestones. The companies will work jointly to develop cell therapies for four designated therapeutic targets, with an option to expand the collaboration at a future date.
“BeiGene is a globally recognized biotechnology leader, and we are thrilled to announce our collaboration,” Kleanthis G. Xanthopoulos, PhD, co-founder and CEO of Shoreline, said in a news release. “We look forward to combining our induced pluripotent stem cells natural killer cells with BeiGene’s discovery and clinical development expertise as the parties work to accelerate the development of the next generation of cell therapies for patients around the world.”
Founded in 2020, Shoreline Biosciences has developed a proprietary platform focused on induced pluripotent stem cells-derived natural killer cells and macrophages that are optimized with precise and rational genetic reprogramming. The company’s technology is at the forefront of regenerative medicine and is being used to develop potential therapies to treat a wide range of diseases including cancer, inflammatory and genetic diseases.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,200 lawyers across 17 offices in the United States, Asia and Europe.